HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.

AbstractBACKGROUND:
Five of seven serotypes in the pneumococcal conjugate vaccine, introduced for infants in the United States in 2000, are responsible for most penicillin-resistant infections. We examined the effect of this vaccine on invasive disease caused by resistant strains.
METHODS:
We used laboratory-based data from Active Bacterial Core surveillance to measure disease caused by antibiotic-nonsusceptible pneumococci from 1996 through 2004. Cases of invasive disease, defined as disease caused by pneumococci isolated from a normally sterile site, were identified in eight surveillance areas. Isolates underwent serotyping and susceptibility testing.
RESULTS:
Rates of invasive disease caused by penicillin-nonsusceptible strains and strains not susceptible to multiple antibiotics peaked in 1999 and decreased by 2004, from 6.3 to 2.7 cases per 100,000 (a decline of 57 percent; 95 percent confidence interval, 55 to 58 percent) and from 4.1 to 1.7 cases per 100,000 (a decline of 59 percent; 95 percent confidence interval, 58 to 60 percent), respectively. Among children under two years of age, disease caused by penicillin-nonsusceptible strains decreased from 70.3 to 13.1 cases per 100,000 (a decline of 81 percent; 95 percent confidence interval, 80 to 82 percent). Among persons 65 years of age or older, disease caused by penicillin-nonsusceptible strains decreased from 16.4 to 8.4 cases per 100,000 (a decline of 49 percent). Rates of resistant disease caused by vaccine serotypes fell 87 percent. An increase was seen in disease caused by serotype 19A, a serotype not included in the vaccine (from 2.0 to 8.3 per 100,000 among children under two years of age).
CONCLUSIONS:
The rate of antibiotic-resistant invasive pneumococcal infections decreased in young children and older persons after the introduction of the conjugate vaccine. There was an increase in infections caused by serotypes not included in the vaccine.
AuthorsMoe H Kyaw, Ruth Lynfield, William Schaffner, Allen S Craig, James Hadler, Arthur Reingold, Ann R Thomas, Lee H Harrison, Nancy M Bennett, Monica M Farley, Richard R Facklam, James H Jorgensen, John Besser, Elizabeth R Zell, Anne Schuchat, Cynthia G Whitney, Active Bacterial Core Surveillance of the Emerging Infections Program Network
JournalThe New England journal of medicine (N Engl J Med) Vol. 354 Issue 14 Pg. 1455-63 (Apr 06 2006) ISSN: 1533-4406 [Electronic] United States
PMID16598044 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2006 Massachusetts Medical Society.
Chemical References
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Meningococcal Vaccines
  • Pneumococcal Vaccines
Topics
  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Drug Resistance, Bacterial
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Humans
  • Infant
  • Meningococcal Vaccines
  • Middle Aged
  • Penicillin Resistance
  • Pneumococcal Infections (epidemiology, microbiology, prevention & control)
  • Pneumococcal Vaccines
  • Population Surveillance
  • Serotyping
  • Streptococcus pneumoniae (classification, drug effects, isolation & purification)
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: